grade
pharmaceutical primary standard
API family
resveratrol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
SMILES string
Oc1ccc(cc1)\C=C\c2cc(O)cc(O)c2
InChI
1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
InChI key
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Selective inhibitor of COX−1.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
>392.0 °F - closed cup - (External MSDS)
flash_point_c
> 200.0 °C - closed cup - (External MSDS)
Alexandra Maier-Salamon et al.
Annals of the New York Academy of Sciences, 1290, 98-106 (2013-07-17)
Resveratrol exhibits a variety of biological and pharmacological activities despite its extensive metabolism to sulfates and glucuronides in the intestine and liver. The metabolism of resveratrol is cell specific and strongly correlates with enzyme expression levels. However, a high rate
Agneta Oskarsson et al.
The Prostate, 74(8), 839-851 (2014-03-13)
Resveratrol (RSV) and resveratrol analogs have a potential use in prostate cancer chemoprevention due to effects on for example, cell growth, apoptosis, angiogenesis, and metastasis. However, inhibition of CYP17A1, a key enzyme in the androgen biosynthesis and a target for
Morten Møller Poulsen et al.
Annals of the New York Academy of Sciences, 1290, 74-82 (2013-07-17)
In the search for novel preventive and therapeutic modalities in the management of metabolic diseases and obesity, resveratrol has attracted great attention over the past decades. Preclinical trials suggest that resveratrol mimics the metabolic effects of calorie restriction (CR) via
